DongKook Pharmaceutical Co. Ltd (086450) — Capital Reinvestment Ratio
DongKook Pharmaceutical Co. Ltd (086450) has a Capital Reinvestment Ratio of 0.60x as of March 2026, meaning it reinvests 1% of its operating cash flow (₩22.58 Billion) in capital expenditures (₩13.54 Billion). Check DongKook Pharmaceutical Co. Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
DongKook Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks DongKook Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see DongKook Pharmaceutical Co. Ltd cash conversion from operations.
Annual Capital Reinvestment Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for DongKook Pharmaceutical Co. Ltd from 2013 to 2025. See 086450 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | ₩68.76 Billion | ₩46.00 Billion | ▲ +65.2% |
| 2024 | 0.40x | ₩76.09 Billion | ₩30.80 Billion | ▼ -57.0% |
| 2023 | 0.94x | ₩41.79 Billion | ₩39.35 Billion | ▼ -24.8% |
| 2022 | 1.25x | ₩40.91 Billion | ₩51.23 Billion | ▲ +9.6% |
| 2021 | 1.14x | ₩44.65 Billion | ₩51.01 Billion | ▲ +70.5% |
| 2020 | 0.67x | ₩59.11 Billion | ₩39.61 Billion | ▲ +85.3% |
| 2019 | 0.36x | ₩69.48 Billion | ₩25.13 Billion | ▼ -84.1% |
| 2018 | 2.27x | ₩33.21 Billion | ₩75.46 Billion | ▲ +457.8% |
| 2017 | 0.41x | ₩28.66 Billion | ₩11.67 Billion | ▲ +66.9% |
| 2016 | 0.24x | ₩39.41 Billion | ₩9.62 Billion | ▼ -30.9% |
| 2015 | 0.35x | ₩27.14 Billion | ₩9.60 Billion | ▼ -40.8% |
| 2014 | 0.60x | ₩22.74 Billion | ₩13.59 Billion | ▲ +197.2% |
| 2013 | 0.20x | ₩19.86 Billion | ₩3.99 Billion | — |